Shaun F. O’Malley, Chairman of the Board
Mr. O'Malley has served as a Director of PolyMedix, Inc. since January 2006 and as Chairman of the Board since June 2011. Mr. O’Malley is currently the Chairman Emeritus of Price Waterhouse LLP, a title he has held since July 1995. Prior to that, he served as Chairman and Senior Partner of Price Waterhouse LLP. He currently serves as a member of the Board of Directors of the Finance Company of Pennsylvania. Mr. O’Malley holds a B.S. in Economics from the Wharton School of the University of Pennsylvania.
Brian Anderson, Director
Mr. Anderson has served as a director of PolyMedix, Inc. since January 2008. He currently serves as an advisor to companies involved in the health care industry. Most recently, Mr. Anderson was employed by Alkermes, Inc., in a market development capacity. Prior to that, he held various positions for numerous life-science companies including, Chief Business officer for MediciNova,Inc., a publicly traded specialty pharmaceutical company, advisor to Montridge, Inc., a boutique investor relations firm, President and CEO of Cognetix, Inc., a biotechnology company, and Senior Vice President for Commercial Development at Indevus (formerly Interneuron) Pharmaceuticals, a publicly traded biopharmaceutical company. In addition he held various senior level positions in sales, marketing and business development at Bristol-Myers Squibb and The Upjohn Company of Canada (which later became Pharmacia and Upjohn and is now a part of Pfizer). Mr. Anderson graduated from the University of Manitoba where he received his Bachelors degree.
Richard W. Bank, M.D., Director
Dr. Bank has served as a director of PolyMedix, Inc. since July 2008. Dr. Bank is currently the President of BioVest Advisors, a consulting company. He most recently served as Senior Portfolio Manager, Managing Director, and Senior Vice President of the Liberty View Health Sciences Fund, a division of Liberty View Capital Management, a Lehman Brothers company. Prior to that, Dr. Bank served as President and Managing Director of First-Tier Biotechnology Partners until its acquisition by Lehman Brothers. Dr. Bank has held various positions for numerous life-science companies including, President and Secretary of Biomedical Sciences, Inc., President and Secretary of BioVest Health Sciences, Inc., and Senior Research Analyst Director/Biotechnology of SBC Warburg Dillon Read. In the early part of his career he served as Entrepreneur-In-Residence in Life Sciences for Tucker Anthony Sutro. Dr. Bank received his B.S. from Washington & Lee University and his M.D. from The Rosalind Franklin University of Medicine and Science, The Chicago Medical School.
Nicholas Landekic, Director, President & CEO of PolyMedix
Nicholas Landekic is a Founder of PolyMedix and has served as President, Chief Executive Officer and Director since inception in 2002. Under his leadership, PolyMedix has internally built a pipeline of cardiovascular and infectious disease drugs, with lead candidates from each program in Phase 2 clinical trials. Since starting PolyMedix, Mr. Landekic has successfully secured over $115 million in funding from public and private capital raises and government contracts and grants. For the past 25 years, Mr. Landekic has held leadership positions in business development, marketing, and finance with biotechnology and pharmaceutical companies. Prior to PolyMedix, Mr. Landekic was President and Chief Executive Officer of Locus Discovery, and also held positions in Corporate/Business Development, Strategic Marketing, and Finance at Guilford Pharmaceuticals, Cephalon, Bristol-Myers Squibb and Johnson & Johnson Corporation (McNeil Pharmaceutical). Earlier in his career, he worked in the research laboratories at Mt. Sinai Medical Center. Mr. Landekic received an MBA from the State University of New York at Albany, an M.A. in Biology from Indiana University and a B.S. in Biology from Marist College.
Michael E. Lewis, Ph.D., Director
Mr. Lewis has served as a director of PolyMedix, Inc. since November 2005 and of PolyMedix Pharmaceuticals, Inc. since its inception. Dr. Lewis has more than 30 years of scientific experience in academic and government laboratories and in several major pharmaceutical and biotechnology companies. Dr. Lewis currently serves as President of BioDiligence Partners, Inc., where he co-founded three other biotechnology companies, Cara Therapeutics, Inc., Arena Pharmaceuticals, Inc. and Adolor Corporation, all of which he has served as Chief Scientific Advisor and Director. Dr. Lewis is a co-founder of Cephalon, Inc. and served at Cephalon as Senior Scientist, Director of Pharmacology, and then as Senior Director of Scientific Affairs. Prior to that, he supervised a molecular pharmacology research laboratory at the E.I. DuPont Company. Dr. Lewis received postdoctoral training in pharmacology at the National Institutes of Health, the University of Michigan, and at the University of Cambridge. He received his Ph.D. from Clark University.
Stefan D. Loren, Ph.D., Director
Mr. Loren has served as a director of PolyMedix, Inc. since July 2008. Dr. Loren is currently a Managing Director of Westwicke Partners, a consulting company and a consultant to MTB Investment Advisors, a family of equity funds. Most recently Dr. Loren was Analyst/Portfolio Manager with Perceptive Advisors, a health care hedge fund and MTB Investment Advisors. Prior to that, he was a Managing Director in the healthcare group at Legg Mason. Dr. Loren was a Research Chemist at the advanced technologies division of Abbott Laboratories and a research fellow at the Scripps Research Institute. Dr. Loren received his B.A. from the University of California, San Diego and his Ph.D. from University of California, Berkeley.
Douglas J. Swirsky, Director
Mr. Swirsky has served as a director of PolyMedix, Inc. since June 2009. Mr. Swirsky presently serves as Senior Vice President, Chief Financial Officer, Treasurer, and Corporate Secretary of GenVec, Inc., a biopharmaceutical company. Prior to joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus and held the same position at Legg Mason prior to Stifel Financial’s acquisition of the Legg Mason Capital Markets business. Mr. Swirsky, a Certified Public Accountant and a CFA charterholder, has also previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his B.S. in Business in Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.